This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:starting:physician:reluctant [04.15.2019] – [Specific research] sallieq | home:starting:physician:reluctant [06.01.2019] – [Specific research] sallieq | ||
---|---|---|---|
Line 176: | Line 176: | ||
[[home: | [[home: | ||
- | OLM refs to print; | + | OLMesartan references |
- | including | + | include |
Line 193: | Line 193: | ||
- | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed> | + | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.[in rat](({{pubmed> |
Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> | ||
Line 209: | Line 209: | ||
- | 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed> | + | 6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{pubmed> |
+ | |||
+ | Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{pubmed> | ||
Line 272: | Line 274: | ||
the volume of larger atherosclerotic plaques (({{pubmed> | the volume of larger atherosclerotic plaques (({{pubmed> | ||
+ | Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris. | ||
+ | |||
+ | This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan. | ||
improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | ||
Line 294: | Line 299: | ||
{{section>: | {{section>: | ||
- | {{tag> | + | {{tag> |
===== Notes and comments ===== | ===== Notes and comments ===== |